Close

BiondVax Pharma (BVXV) Presents Preliminary Phase II Data from BVX-006 Trial of M-001

June 29, 2015 3:53 PM EDT Send to a Friend
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login